[email protected] +1 646 480 7505 (U.S.) | +44 203 318 2846 (U.K.)

TABLE OF CONTENTS

1              Introduction

1.1          Market Definition

1.2          Market Scope

2              Research Methodology

2.1          Primary Research

2.2          Research Methodology

2.3          Assumptions & Exclusions

2.4          Secondary Data Sources

3              Market Overview

3.1          Report Segmentation & Scope

3.2          Value Chain Analysis: Diabetic Retinopathy Market

3.3          Key Market Trends

3.3.1      Drivers

3.3.2      Restraints

3.3.3      Opportunities

3.4          Porter’s Five Forces Analysis

3.4.1      Bargaining Power of Suppliers

3.4.2      Bargaining Power of Buyers

3.4.3      Threat of Substitution

3.4.4      Threat of New Entrants

3.4.5      Competitive Rivalry

3.5          Market Share Analysis

4              By Type

4.1          Introduction

4.1.1      Market Size & Forecast (Value)

4.2          proliferative diabetic retinopathy

4.3       Diabetic Macular Edema (DME)

 5.           By Treatment Type        

5.1          Introduction

5.1.1      Market Size & Forecast (Value)

5.2          By Type

5.3          Steroid Implants

6              By Regional Overview  

6.1          Introduction      

6.1.1      Market Size & Forecast (Value) 

6.2          America              

6.2.1      North America  

6.2.1.1   U.S.       

6.2.1.1.1               By Type

6.2.1.1.2              By Treatment Type         

6.2.1.2   Canada

6.2.1.2.1               By Type

6.2.1.2.2              By Treatment Type         

6.2.1.3   Mexico

6.2.1.3.1               By Type

6.2.1.3.2              By Treatment Type         

6.2.1.4   Latin America   

6.2.1.4.1               By Type

6.2.1.4.2               By Treatment Type

6.3          Europe

6.3.1      Market Size & Forecast (Value) 

6.3.2      Germany            

6.3.2.1                   By Type

6.3.2.2                   By Treatment Type         

6.3.3      France 

6.3.3.1                   By Type

6.3.3.2                   By Treatment Type         

6.3. 4     U.K.      

6.3.4.1                   By Type

6.3.4.2                 By Treatment Type         

6.3.5      Italy      

6.3.5.1                   By Type

6.3.5.2                   By Treatment Type         

6.3.6      Spain    

6.3.6.1                   By Type

6.3.6.2                   By Treatment Type         

6.3.6      Rest of Europe 

6.3.6.1                   By Type

6.3.6.2                   By Treatment Type

6.4          Asia Pacific         

6.4.1      Market Size & Forecast (Value) 

6.4.2      Japan   

6.4.2.1                   By Type

6.4.2.2                  By Treatment Type         

6.4.3      China    

6.4.3.1                   By Type

6.4.3.2                  By Treatment Type

6.4.4      Australia             

6.4.4.1                   By Type

6.4.4.2                   By Treatment Type         

6.4.5      India     

6.4.5.1                   By Type

6.4.5.2                 By Treatment Type         

6.4.6      South Korea      

6.4.6.1                   By Type

6.4.6.2                 By Treatment Type         

6.4.6      Rest of Asia-Pacific         

6.4.6.1                   By Type

6.4.6.2                   By Treatment Type         

6.5          Middle East & Africa      

6.5.1      Market Size & Forecast (Value) 

6.5.2      Saudi Arabia      

6.5.2.1                   By Type

6.5.2.2                   By Treatment Type         

6.5.3      South Africa       

6.5.3.1                   By Type

6.5.5.2                 By Treatment Type         

6.5.4      Kuwait 

6.5.4.1                   By Type

6.5.5.2                 By Treatment Type         

6.5.5      Rest of Middle East & Africa       

6.5.5.1                   By Type

6.5.5.2                 By Treatment Type         

7.            Company Profile                            

7.1          Novartis AG

7.1.1      Company Overview       

7.1.2      Financial Performance  

7.1.3      Recent Developments  

7.1.4      Product Portfolio             

7.2          Karl Storz

7.2.1      Company Overview       

7.2.2      Financial Performance  

7.2.3      Recent Developments  

7.2.4      Product Portfolio             

7.3          Bayer AG

7.3.1      Company Overview       

7.3.2      Financial Performance  

7.3.3      Recent Developments  

7.3.4      Product Portfolio             

7.4          Pfizer, Inc.

7.4.1      Company Overview       

7.4.2      Financial Performance  

7.4.3      Recent Developments  

7.4.4      Product Portfolio             

7.5          Allergan Inc.

7.5.1      Company Overview       

7.5.2      Financial Performance  

7.5.3      Recent Developments  

7.5.4      Product Portfolio             

7.6          Isis Pharmaceuticals, Inc.

7.6.1      Company Overview       

7.6.2      Financial Performance  

7.6.3      Recent Developments  

7.6.4      Product Portfolio             

7.7          Valeant Pharmaceuticals, Inc.

7.7.1      Company Overview       

7.7.2      Financial Performance  

7.7.3      Recent Developments  

7.7.4      Product Portfolio

7.8          Abbott Laboratories, Inc.

7.8.1      Company Overview       

7.8.2      Financial Performance  

7.8.3      Recent Developments  

7.8.4      Product Portfolio

7.9          Regeneron Pharmaceuticals, Inc.

7.9.1      Company Overview       

7.9.2      Financial Performance  

7.9.3      Recent Developments  

7.9.4      Product Portfolio             



Request For Free Sample
Choose license Type

Buy Chapters or Sections

Avail customized purchase option to meet your exact research needs:

1)Buy sections of the report
2)Buy country level report
3)Request for historical data

Request a Free Sample   Special Pricing
Related Reports